Treating metastatic renal cell carcinoma: Patient case studies

Program launch date: 16th November 2020
The development of several targeted treatment options has revolutionized the treatment of metastatic RCC.  Dr Axel Merseburger invites you to participate in this three-part case study series which looks at how to manage metastatic renal cell carcinoma (RCC).

  • In the first case study, we follow a good prognosis patient diagnosed with clear cell RCC through initial treatment decisions.
  • In the second case study we look at what happens when we see disease progression following first-line treatment.
  • The final case study takes us through the process of determining patient prognosis, and deciding on an appropriate treatment pathway for a poor prognosis patient using new therapy combinations.

Each case study will take up to 15 minutes to complete. To claim your credits, select the box in the evaluation form at the end of the activity. Review the evidence, test your knowledge through these case based self-assessments and help guide your everyday clinical practice.

Case studies

Case 1: First-line Management of Metastatic RCC


Professor Axel Merseburger presents an interactive case study on selecting the correct first-line treatment options.
Publishing date: 16th November 2020

Case 2: Second-line (and Beyond) Management of Metastatic RCC


Professor Axel Merseburger presents an interactive case study on selecting the correct second-line treatment options.
Publishing date: 1st December 2020

Case 3: New and Emerging Treatments in Metastatic RCC


Professor Axel Merseburger presents an interactive case study on how to incorporate new and emerging therapies into treatment regimens.
Publishing date: 18th December 2020

Login to access these case studies

About this activity

Dr Axel Merseburger

Dr Axel Merseburger is the chairman of the Department of Urology at the University Hospital Schleswig-Holstein in Lübeck, Germany.

His key areas of interest are renal cell carcinoma, prostate cancer and transitional cell carcinoma, with special attention given to novel markers and prognostic factors.

He is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer and has served as national and international principal investigator in several phase II/III clinical trials.

His molecular and clinical research has won multiple awards, stipends and prizes, and he has authored and co-authored more that 200 publications.

  • Clinical trials: Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Roche, BMS, Merck
  • Referent, Speaker, Symposia: Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Roche, Sanofi, Takeda, TEVA, Springer Healthcare
  • Advisory boards: Bayer, TEVA, UEG, Janssen, BMS, Merck, Roche, Astellas
  • Company shares: none
Case 1: First-line Management of Metastatic RCC

After completing this case study, you will be able to:

  • Understand the first-line treatment pathway for patients with metastatic RCC, including:
  • Tumor biology and disease stabilization, and as such when to pause treatment
  • How adverse events in influence treatment decisions

Case 2: Second-line (and Beyond) Management of Metastatic RCC          

After completing this case study, you will be able to:

  • Understand the second-line (and beyond) treatment pathway for patients with metastatic RCC, including:
  • The use and rationale for immuno-oncology in patients with RCC
  • How to manage adverse events

Case 3: New and Emerging Treatments in Metastatic RCC

After completing this case study, you will be able to:

  • Understand the treatment pathway for poor prognosis metastatic RCC patients with no symptoms, including:
  • When to perform a cytoreductive nephrectomy
  • Systemic combination therapies

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NACCME designates AMA PRA Category Credit(s)™ for the following activities:

Completion of each case study: AMA PRA Category 0.25 Credits™
Expiration date: 18th December 2022
How To Claim Your Credits

To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.

During completion of the evaluation form, you can select the box that indicates accreditation is required.

Use of Proprietary Names

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

Unapproved and/or Investigational Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

Disclosure of Relevant Financial Relationships

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Planning Committee

In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, Marie Le Solliec and Rebecca Cox

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Marie Le Solliec and Rebecca Cox have no financial relationships to disclose.

ADA Statement

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof.

Privacy Policy

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and its joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 Springer Healthcare IME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Springer Healthcare IME.

These case studies are supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.